Notícias e Atividades da Niagen Bioscience

Niagen Bioscience é uma empresa listada sob o símbolo NAGE (US).

Veja o organograma con seus 14 executivos principais

Biografias mais buscadas da Niagen Bioscience

• Robert Fried, Chief Executive Officer and Director
• Kristin Patrick, Director
• Frank Jaksch, Executive Chairman of the Board

Recentes movimentos de executivos em Niagen Bioscience

• Ozan Pamir, ingressou na Companhia como Chief Financial Officer  (Notícia publicada em 23 de setembro de 2024).

Criar um alerta
para seguir os movimentos de executivos da Niagen Bioscience.

Niagen Bioscience possui 1.824 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Roche (Suíça).

Popular M&A news in Farmacêutica

• Cyclo Therapeutics adquiriu Rafael Holdings (publicado em 28 de abril de 2025).
• Chimerix and Chimerix have merged  (publicado em 22 de abril de 2025)..
• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Seth Harrison - Chairman and Director da Braeburn Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Niagen Bioscience

• ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category
• ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement
• ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
• ChromaDex Corporation Reports Third Quarter 2024 Financial Results
• ChromaDex Corporation Reports Third Quarter 2024 Financial Results
• ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
• ChromaDex to Participate in the 17th Annual LD Micro Main Event
• ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
• Niagen+ | Pharmaceutical-grade Niagen (NR) IV and Injectable
• Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)
• View more press releases Close

Redes sociais sobre Niagen Bioscience

• Niagen Bioscience na Wikipedia, Google News e Yahoo Finance
• Niagen Bioscience na LinkedIn, Twitter e YouTube